Exelixis, Inc.
EXELNASDAQHealthcare● Active
$52.12
$-0.58(-1.10%)
Market Cap$13.1B
P/E Ratio—
52W High$52.98
52W Low$33.76
Exelixis, Inc. (EXEL) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
EXEL · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 5, 2026EPS Actual
$0.87
Est. $0.77 · +13.7%
Revenue
$0.61B
Est. $0.61B · +0.5%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 5, 2026
After Market Close
▲ Beat EPS🔥 8-Quarter EPS Beat Streak
EXEL reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.27B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.27B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 4, 2026 | $0.85 | — | — | — | $0.63B | — |
| ▲ Q2 FY2026 | May 5, 2026 | $0.77 | $0.87 | +13.7% | $0.61B | $0.61B | +0.5% |
| ▲ Q1 FY2026 | Feb 10, 2026 | $0.77 | $0.94 | +22.1% | $0.60B | $0.60B | +0.4% |
| ▲ Q4 FY2025 | Nov 4, 2025 | $0.69 | $0.78 | +13.9% | $0.60B | $0.59B | +1.3% |
| ▲ Q3 FY2025 | Jul 28, 2025 | $0.65 | $0.75 | +15.4% | $0.57B | $0.59B | -4.5% |
| ▲ Q2 FY2025 | May 13, 2025 | $0.36 | $0.62 | +73.1% | $0.56B | $0.50B | +11.2% |
| ▲ Q1 FY2025 | Feb 11, 2025 | $0.51 | $0.55 | +7.8% | $0.57B | $0.56B | +0.6% |
| ▲ Q4 FY2024 | Oct 29, 2024 | $0.35 | $0.40 | +14.3% | $0.54B | $0.56B | -3.1% |
Q3 FY2026
Aug 4, 2026
EPS Actual
—
EPS Est.
$0.85
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 5, 2026Beat
EPS Actual
$0.87
EPS Est.
$0.77
EPS Surpr.
+13.7%
Revenue
$0.61B
Q1 FY2026
Feb 10, 2026Beat
EPS Actual
$0.94
EPS Est.
$0.77
EPS Surpr.
+22.1%
Revenue
$0.60B
Q4 FY2025
Nov 4, 2025Beat
EPS Actual
$0.78
EPS Est.
$0.69
EPS Surpr.
+13.9%
Revenue
$0.60B
Q3 FY2025
Jul 28, 2025Beat
EPS Actual
$0.75
EPS Est.
$0.65
EPS Surpr.
+15.4%
Revenue
$0.57B
Q2 FY2025
May 13, 2025Beat
EPS Actual
$0.62
EPS Est.
$0.36
EPS Surpr.
+73.1%
Revenue
$0.56B
Q1 FY2025
Feb 11, 2025Beat
EPS Actual
$0.55
EPS Est.
$0.51
EPS Surpr.
+7.8%
Revenue
$0.57B
Q4 FY2024
Oct 29, 2024Beat
EPS Actual
$0.40
EPS Est.
$0.35
EPS Surpr.
+14.3%
Revenue
$0.54B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2029 | $1.05 | $1.09 | $1.15 | 2 |
| Q4 FY2028 | $1.01 | $1.05 | $1.11 | 3 |
| Q3 FY2028 | $0.98 | $1.02 | $1.07 | 3 |
| Q2 FY2028 | $0.96 | $0.99 | $1.05 | 3 |
| Q1 FY2028 | $1.03 | $1.07 | $1.13 | 4 |
| Q4 FY2027 | $0.98 | $1.02 | $1.07 | 3 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2029 | $0.9B | $0.9B | $0.9B | 9 |
| Q4 FY2028 | $0.8B | $0.9B | $0.9B | 5 |
| Q3 FY2028 | $0.8B | $0.8B | $0.9B | 4 |
| Q2 FY2028 | $0.8B | $0.8B | $0.8B | 4 |
| Q1 FY2028 | $0.8B | $0.8B | $0.8B | 7 |
| Q4 FY2027 | $0.7B | $0.7B | $0.8B | 5 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 5, 2026 | +13.7% | $44.17 | $44.42 | +0.57% |
| ▲ Q1 FY2026 | Feb 10, 2026 | +22.1% | $43.95 | $42.98 | -2.21% |
| ▲ Q4 FY2025 | Nov 4, 2025 | +13.9% | $38.06 | $37.90 | -0.42% |
| ▲ Q3 FY2025 | Jul 28, 2025 | +15.4% | $45.60 | $44.39 | -2.65% |
| ▲ Q2 FY2025 | May 13, 2025 | +73.1% | $36.98 | $36.95 | -0.08% |
| ▲ Q1 FY2025 | Feb 11, 2025 | +7.8% | $33.50 | $32.81 | -2.06% |
| ▲ Q4 FY2024 | Oct 29, 2024 | +14.3% | $28.50 | $28.73 | +0.81% |
| ▲ Q3 FY2024 | Aug 6, 2024 | +156.7% | $23.52 | $23.45 | -0.30% |
Q2 FY2026+0.57%
Report Date
May 5, 2026
EPS Beat/Miss
+13.7%
Price Before
$44.17
Price After
$44.42
Q1 FY2026-2.21%
Report Date
Feb 10, 2026
EPS Beat/Miss
+22.1%
Price Before
$43.95
Price After
$42.98
Q4 FY2025-0.42%
Report Date
Nov 4, 2025
EPS Beat/Miss
+13.9%
Price Before
$38.06
Price After
$37.90
Q3 FY2025-2.65%
Report Date
Jul 28, 2025
EPS Beat/Miss
+15.4%
Price Before
$45.60
Price After
$44.39
Q2 FY2025-0.08%
Report Date
May 13, 2025
EPS Beat/Miss
+73.1%
Price Before
$36.98
Price After
$36.95
Q1 FY2025-2.06%
Report Date
Feb 11, 2025
EPS Beat/Miss
+7.8%
Price Before
$33.50
Price After
$32.81
Q4 FY2024+0.81%
Report Date
Oct 29, 2024
EPS Beat/Miss
+14.3%
Price Before
$28.50
Price After
$28.73
Q3 FY2024-0.30%
Report Date
Aug 6, 2024
EPS Beat/Miss
+156.7%
Price Before
$23.52
Price After
$23.45
Avg Beat Reaction-0.79%
Beat Rate8 / 8 quarters
Largest Move-2.65% (Q3 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: EXEL ends December
Exelixis, Inc. (EXEL) most recently reported earnings on May 5, 2026 for Q2 FY2026, posting EPS of $0.87 — beating the analyst consensus of $0.77 by +13.7%. EXEL has beaten EPS estimates for 8 consecutive quarters. The next EXEL earnings date is expected around September 1, 2026.
Each quarter, investors track EXEL earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. EXEL revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
EXEL's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
EXEL earnings · 5 questionsExelixis, Inc.'s next earnings report is expected around September 1, 2026. EXEL typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; EXEL historically reports after market close (AMC).
EXEL earnings datewhen is EXEL earningsEXEL next earnings datewhen does EXEL report earningsEXEL earnings calendar
▸ Source: FMP · Exelixis, Inc. SEC filings · US GAAP · Exelixis, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026